Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 293

1.

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.

Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC; FLAURA Investigators.

N Engl J Med. 2019 Nov 21. doi: 10.1056/NEJMoa1913662. [Epub ahead of print]

PMID:
31751012
2.

A Combination of Metabolites Predicts Adherence to the Mediterranean Diet Pattern and Its Associations with Insulin Sensitivity and Lipid Homeostasis in the General Population: The Fenland Study, United Kingdom.

Tong TYN, Koulman A, Griffin JL, Wareham NJ, Forouhi NG, Imamura F.

J Nutr. 2019 Oct 26. pii: nxz263. doi: 10.1093/jn/nxz263. [Epub ahead of print]

PMID:
31665391
3.

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.

Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators.

Lancet Oncol. 2019 Dec;20(12):1655-1669. doi: 10.1016/S1470-2045(19)30634-5. Epub 2019 Oct 4.

PMID:
31591063
4.
5.

Validity and reliability of an online self-report 24-h dietary recall method (Intake24): a doubly labelled water study and repeated-measures analysis.

Foster E, Lee C, Imamura F, Hollidge SE, Westgate KL, Venables MC, Poliakov I, Rowland MK, Osadchiy T, Bradley JC, Simpson EL, Adamson AJ, Olivier P, Wareham N, Forouhi NG, Brage S.

J Nutr Sci. 2019 Aug 30;8:e29. doi: 10.1017/jns.2019.20. eCollection 2019.

6.

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer.

Gray JE, Okamoto I, Sriuranpong V, Vansteenkiste J, Imamura F, Lee JS, Pang YK, Cobo M, Kasahara K, Cheng Y, Nogami N, Cho EK, Su WC, Zhang G, Huang X, Li-Sucholeiki X, Lentrichia B, Dearden S, Jenkins S, Saggese M, Rukazenkov Y, Ramalingam SS.

Clin Cancer Res. 2019 Nov 15;25(22):6644-6652. doi: 10.1158/1078-0432.CCR-19-1126. Epub 2019 Aug 22.

PMID:
31439584
7.

Association of alcohol consumption with prevalence of fatty liver after adjustment for dietary patterns: Cross-sectional analysis of Japanese middle-aged adults.

Tajima R, Imamura F, Kimura T, Kobayashi S, Masuda K, Iida K.

Clin Nutr. 2019 Jul 26. pii: S0261-5614(19)30282-1. doi: 10.1016/j.clnu.2019.07.001. [Epub ahead of print]

8.

Estimated Substitution of Tea or Coffee for Sugar-Sweetened Beverages Was Associated with Lower Type 2 Diabetes Incidence in Case-Cohort Analysis across 8 European Countries in the EPIC-InterAct Study.

Imamura F, Schulze MB, Sharp SJ, Guevara M, Romaguera D, Bendinelli B, Salamanca-Fernández E, Ardanaz E, Arriola L, Aune D, Boeing H, Dow C, Fagherazzi G, Franks PW, Freisling H, Jakszyn P, Kaaks R, Khaw KT, Kühn T, Mancini FR, Masala G, Chirlaque MD, Nilsson PM, Overvad K, Pala VM, Panico S, Perez-Cornago A, Quirós JR, Ricceri F, Rodríguez-Barranco M, Rolandsson O, Sluijs I, Stepien M, Spijkerman AMW, Tjønneland A, Tong TYN, Tumino R, Vissers LET, Ward HA, Langenberg C, Riboli E, Forouhi NG, Wareham NJ.

J Nutr. 2019 Nov 1;149(11):1985-1993. doi: 10.1093/jn/nxz156.

9.

Preventable Cancer Burden Associated With Poor Diet in the United States.

Zhang FF, Cudhea F, Shan Z, Michaud DS, Imamura F, Eom H, Ruan M, Rehm CD, Liu J, Du M, Kim D, Lizewski L, Wilde P, Mozaffarian D.

JNCI Cancer Spectr. 2019 May 22;3(2):pkz034. doi: 10.1093/jncics/pkz034. eCollection 2019 Jun.

10.

Quality of dietary fat and genetic risk of type 2 diabetes: individual participant data meta-analysis.

Merino J, Guasch-Ferré M, Ellervik C, Dashti HS, Sharp SJ, Wu P, Overvad K, Sarnowski C, Kuokkanen M, Lemaitre RN, Justice AE, Ericson U, Braun KVE, Mahendran Y, Frazier-Wood AC, Sun D, Chu AY, Tanaka T, Luan J, Hong J, Tjønneland A, Ding M, Lundqvist A, Mukamal K, Rohde R, Schulz CA, Franco OH, Grarup N, Chen YI, Bazzano L, Franks PW, Buring JE, Langenberg C, Liu CT, Hansen T, Jensen MK, Sääksjärvi K, Psaty BM, Young KL, Hindy G, Sandholt CH, Ridker PM, Ordovas JM, Meigs JB, Pedersen O, Kraft P, Perola M, North KE, Orho-Melander M, Voortman T, Toft U, Rotter JI, Qi L, Forouhi NG, Mozaffarian D, Sørensen TIA, Stampfer MJ, Männistö S, Selvin E, Imamura F, Salomaa V, Hu FB, Wareham NJ, Dupuis J, Smith CE, Kilpeläinen TO, Chasman DI, Florez JC.

BMJ. 2019 Jul 25;366:l4292. doi: 10.1136/bmj.l4292. Erratum in: BMJ. 2019 Oct 9;367:l5612.

11.

Associations of types of dairy consumption with adiposity: cross-sectional findings from over 12 000 adults in the Fenland Study, UK.

Trichia E, Imamura F, Brage S, De Lucia Rolfe E, Griffin SJ, Wareham NJ, Forouhi NG.

Br J Nutr. 2019 Oct 28;122(8):928-935. doi: 10.1017/S0007114519001776.

12.

Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.

Hirashima T, Satouchi M, Hida T, Nishio M, Kato T, Sakai H, Imamura F, Kiura K, Okamoto I, Kasahara K, Uchida H, Vowler SL, Mitsudomi T.

Cancer Sci. 2019 Sep;110(9):2884-2893. doi: 10.1111/cas.14120. Epub 2019 Aug 1.

13.

Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?

Tamiya M, Tamiya A, Suzuki H, Moriizumi K, Nakahama K, Taniguchi Y, Kunimasa K, Kimura M, Inoue T, Kuhara H, Nishino K, Hirashima T, Atagi S, Imamura F, Kumagai T.

Anticancer Res. 2019 Jul;39(7):3923-3929. doi: 10.21873/anticanres.13544.

PMID:
31262922
14.

Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT).

Okada M, Kijima T, Aoe K, Kato T, Fujimoto N, Nakagawa K, Takeda Y, Hida T, Kanai K, Imamura F, Oizumi S, Takahashi T, Takenoyama M, Tanaka H, Hirano J, Namba Y, Ohe Y.

Clin Cancer Res. 2019 Sep 15;25(18):5485-5492. doi: 10.1158/1078-0432.CCR-19-0103. Epub 2019 Jun 4.

PMID:
31164373
15.

Patients with SMARCA4-deficient thoracic sarcoma and severe skeletal-related events.

Kunimasa K, Nakamura H, Sakai K, Tamiya M, Kimura M, Inoue T, Nishino K, Kuhara H, Nakatsuka SI, Nishio K, Imamura F, Kumagai T.

Lung Cancer. 2019 Jun;132:59-64. doi: 10.1016/j.lungcan.2019.03.029. Epub 2019 Apr 8.

PMID:
31097095
16.

Driving status, travel modes and accelerometer-assessed physical activity in younger, middle-aged and older adults: a prospective study of 90 810 UK Biobank participants.

Hajna S, White T, Panter J, Brage S, Wijndaele K, Woodcock J, Ogilvie D, Imamura F, Griffin SJ.

Int J Epidemiol. 2019 Aug 1;48(4):1175-1186. doi: 10.1093/ije/dyz065.

17.

Changes in plasma phospholipid fatty acid profiles over 13 years and correlates of change: European Prospective Investigation into Cancer and Nutrition-Norfolk Study.

Zheng JS, Imamura F, Sharp SJ, Koulman A, Griffin JL, Mulligan AA, Luben R, Khaw KT, Wareham NJ, Forouhi NG.

Am J Clin Nutr. 2019 Jun 1;109(6):1527-1534. doi: 10.1093/ajcn/nqz030.

18.

Associations of circulating very-long-chain saturated fatty acids and incident type 2 diabetes: a pooled analysis of prospective cohort studies.

Fretts AM, Imamura F, Marklund M, Micha R, Wu JHY, Murphy RA, Chien KL, McKnight B, Tintle N, Forouhi NG, Qureshi WT, Virtanen JK, Wong K, Wood AC, Lankinen M, Rajaobelina K, Harris TB, Djoussé L, Harris B, Wareham NJ, Steffen LM, Laakso M, Veenstra J, Samieri C, Brouwer IA, Yu CI, Koulman A, Steffen BT, Helmer C, Sotoodehnia N, Siscovick D, Gudnason V; InterAct Consortium, Wagenknecht L, Voutilainen S, Tsai MY, Uusitupa M, Kalsbeek A, Berr C, Mozaffarian D, Lemaitre RN.

Am J Clin Nutr. 2019 Apr 1;109(4):1216-1223. doi: 10.1093/ajcn/nqz005.

PMID:
30982858
19.

Biomarkers of Dietary Omega-6 Fatty Acids and Incident Cardiovascular Disease and Mortality.

Marklund M, Wu JHY, Imamura F, Del Gobbo LC, Fretts A, de Goede J, Shi P, Tintle N, Wennberg M, Aslibekyan S, Chen TA, de Oliveira Otto MC, Hirakawa Y, Eriksen HH, Kröger J, Laguzzi F, Lankinen M, Murphy RA, Prem K, Samieri C, Virtanen J, Wood AC, Wong K, Yang WS, Zhou X, Baylin A, Boer JMA, Brouwer IA, Campos H, Chaves PHM, Chien KL, de Faire U, Djoussé L, Eiriksdottir G, El-Abbadi N, Forouhi NG, Michael Gaziano J, Geleijnse JM, Gigante B, Giles G, Guallar E, Gudnason V, Harris T, Harris WS, Helmer C, Hellenius ML, Hodge A, Hu FB, Jacques PF, Jansson JH, Kalsbeek A, Khaw KT, Koh WP, Laakso M, Leander K, Lin HJ, Lind L, Luben R, Luo J, McKnight B, Mursu J, Ninomiya T, Overvad K, Psaty BM, Rimm E, Schulze MB, Siscovick D, Skjelbo Nielsen M, Smith AV, Steffen BT, Steffen L, Sun Q, Sundström J, Tsai MY, Tunstall-Pedoe H, Uusitupa MIJ, van Dam RM, Veenstra J, Monique Verschuren WM, Wareham N, Willett W, Woodward M, Yuan JM, Micha R, Lemaitre RN, Mozaffarian D, Risérus U; Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Fatty Acids and Outcomes Research Consortium (FORCE).

Circulation. 2019 May 21;139(21):2422-2436. doi: 10.1161/CIRCULATIONAHA.118.038908.

PMID:
30971107
20.

Regional differences in mitral cell development in mouse olfactory bulb.

Nguyen UP, Imamura F.

J Comp Neurol. 2019 Oct 1;527(14):2233-2244. doi: 10.1002/cne.24683. Epub 2019 Mar 22.

PMID:
30864157
21.

Assessing the causal association of glycine with risk of cardio-metabolic diseases.

Wittemans LBL, Lotta LA, Oliver-Williams C, Stewart ID, Surendran P, Karthikeyan S, Day FR, Koulman A, Imamura F, Zeng L, Erdmann J, Schunkert H, Khaw KT, Griffin JL, Forouhi NG, Scott RA, Wood AM, Burgess S, Howson JMM, Danesh J, Wareham NJ, Butterworth AS, Langenberg C.

Nat Commun. 2019 Mar 5;10(1):1060. doi: 10.1038/s41467-019-08936-1.

22.

Narrowly Confined and Glomerulus-Specific Onset Latencies of Odor-Evoked Calcium Transients in the Juxtaglomerular Cells of the Mouse Main Olfactory Bulb.

Homma R, Lv X, Sato T, Imamura F, Zeng S, Nagayama S.

eNeuro. 2019 Feb 28;6(1). pii: ENEURO.0387-18.2019. doi: 10.1523/ENEURO.0387-18.2019. eCollection 2019 Jan-Feb.

23.

Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC.

Sugawara S, Nakagawa K, Yamamoto N, Nokihara H, Ohe Y, Nishio M, Takahashi T, Goto K, Maemondo M, Ichinose Y, Seto T, Sakai H, Gemma A, Imamura F, Shingyoji M, Saka H, Inoue A, Takeda K, Okamoto I, Kiura K, Morita S, Tamura T.

Int J Clin Oncol. 2019 May;24(5):485-493. doi: 10.1007/s10147-019-01396-z. Epub 2019 Mar 4.

24.

Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations.

Nishio M, Murakami H, Ohe Y, Hida T, Sakai H, Kasahara K, Imamura F, Baba T, Kubota K, Hosomi Y, Shimokawa T, Hayashi H, Miyadera K, Tamura T.

Invest New Drugs. 2019 Dec;37(6):1207-1217. doi: 10.1007/s10637-019-00732-4. Epub 2019 Feb 21.

25.

Dairy Product Intake and Risk of Type 2 Diabetes in EPIC-InterAct: A Mendelian Randomization Study.

Vissers LET, Sluijs I, van der Schouw YT, Forouhi NG, Imamura F, Burgess S, Barricarte A, Boeing H, Bonet C, Chirlaque MD, Fagherazzi G, Franks PW, Freisling H, Gunter MJ, Quirós JR, Ibsen DB, Kaaks R, Key T, Khaw KT, Kühn T, Mokoroa O, Nilsson PM, Overvad K, Pala V, Palli D, Panico S, Sacerdote C, Spijkerman AMW, Tjonneland A, Tumino R, Rodríguez-Barranco M, Rolandsson O, Riboli E, Sharp SJ, Langenberg C, Wareham NJ.

Diabetes Care. 2019 Apr;42(4):568-575. doi: 10.2337/dc18-2034. Epub 2019 Feb 6.

26.

The obesity transition: stages of the global epidemic.

Jaacks LM, Vandevijvere S, Pan A, McGowan CJ, Wallace C, Imamura F, Mozaffarian D, Swinburn B, Ezzati M.

Lancet Diabetes Endocrinol. 2019 Mar;7(3):231-240. doi: 10.1016/S2213-8587(19)30026-9. Epub 2019 Jan 28. Review.

27.

The association between adherence to the Mediterranean diet and hepatic steatosis: cross-sectional analysis of two independent studies, the UK Fenland Study and the Swiss CoLaus Study.

Khalatbari-Soltani S, Imamura F, Brage S, De Lucia Rolfe E, Griffin SJ, Wareham NJ, Marques-Vidal P, Forouhi NG.

BMC Med. 2019 Jan 24;17(1):19. doi: 10.1186/s12916-019-1251-7.

28.

Predictors of Acute Radiation Esophagitis in Non-small Cell Lung Cancer Patients Treated With Accelerated Hyperfractionated Chemoradiotherapy.

Wada K, Kishi N, Kanayama N, Hirata T, Ueda Y, Kawaguchi Y, Morimoto M, Konishi K, Imamura F, Ogawa K, Teshima T.

Anticancer Res. 2019 Jan;39(1):491-497. doi: 10.21873/anticanres.13139.

PMID:
30591500
29.

A Meta-Analysis of Food Labeling Effects on Consumer Diet Behaviors and Industry Practices.

Shangguan S, Afshin A, Shulkin M, Ma W, Marsden D, Smith J, Saheb-Kashaf M, Shi P, Micha R, Imamura F, Mozaffarian D; Food PRICE (Policy Review and Intervention Cost-Effectiveness) Project.

Am J Prev Med. 2019 Feb;56(2):300-314. doi: 10.1016/j.amepre.2018.09.024. Epub 2018 Dec 17. Review.

PMID:
30573335
30.

Semaphorin 7A promotes EGFR-TKI resistance in EGFR mutant lung adenocarcinoma cells.

Kinehara Y, Nagatomo I, Koyama S, Ito D, Nojima S, Kurebayashi R, Nakanishi Y, Suga Y, Nishijima-Futami Y, Osa A, Nakatani T, Kato Y, Nishide M, Hayama Y, Higashiguchi M, Morimura O, Miyake K, Kang S, Minami T, Hirata H, Iwahori K, Takimoto T, Takamatsu H, Takeda Y, Hosen N, Hoshino S, Shintani Y, Okumura M, Kumagai T, Nishino K, Imamura F, Nakatsuka SI, Kijima T, Kida H, Kumanogoh A.

JCI Insight. 2018 Dec 20;3(24). pii: 123093. doi: 10.1172/jci.insight.123093.

31.

D1 dopamine receptors intrinsic activity and functional selectivity affect working memory in prefrontal cortex.

Yang Y, Lee SM, Imamura F, Gowda K, Amin S, Mailman RB.

Mol Psychiatry. 2018 Dec 7. doi: 10.1038/s41380-018-0312-1. [Epub ahead of print]

PMID:
30532019
32.

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset.

Ohe Y, Imamura F, Nogami N, Okamoto I, Kurata T, Kato T, Sugawara S, Ramalingam SS, Uchida H, Hodge R, Vowler SL, Walding A, Nakagawa K.

Jpn J Clin Oncol. 2019 Jan 1;49(1):29-36. doi: 10.1093/jjco/hyy179.

33.

First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancer.

Kishi K, Sakai H, Seto T, Kozuki T, Nishio M, Imamura F, Nokihara H, Satouchi M, Nakagawa S, Tahata T, Nakagawa K.

Cancer Treat Res Commun. 2019;18:100113. doi: 10.1016/j.ctarc.2018.10.004. Epub 2018 Oct 31.

34.

Association of Plasma Vitamin D Metabolites With Incident Type 2 Diabetes: EPIC-InterAct Case-Cohort Study.

Zheng JS, Imamura F, Sharp SJ, van der Schouw YT, Sluijs I, Gundersen TE, Ardanaz E, Boeing H, Bonet C, Gómez JH, Dow C, Fagherazzi G, Franks PW, Jenab M, Kühn T, Kaaks R, Key TJ, Khaw KT, Lasheras C, Mokoroa O, Mancini FR, Nilsson PM, Overvad K, Panico S, Palli D, Rolandsson O, Sieri S, Salamanca-Fernández E, Sacerdote C, Spijkerman AMW, Stepien M, Tjonneland A, Tumino R, Butterworth AS, Riboli E, Danesh J, Langenberg C, Forouhi NG, Wareham NJ.

J Clin Endocrinol Metab. 2019 Apr 1;104(4):1293-1303. doi: 10.1210/jc.2018-01522.

35.

Circulating Phylloquinone Concentrations and Risk of Type 2 Diabetes: A Mendelian Randomization Study.

Zwakenberg SR, Remmelzwaal S, Beulens JWJ, Booth SL, Burgess S, Dashti HS, Imamura F, Feskens EJM, van der Schouw YT, Sluijs I.

Diabetes. 2019 Jan;68(1):220-225. doi: 10.2337/db18-0543. Epub 2018 Oct 23.

36.

Aldehyde dehydrogenase 2 genotype in tolerability of alcohol contained in paclitaxel in Japanese breast cancer patients.

Yagi T, Fujiishi K, Hasegawa A, Otsuka T, Yoshinami T, Nishio M, Fujisawa F, Sugimoto N, Imamura F.

Breast Cancer. 2019 Mar;26(2):229-234. doi: 10.1007/s12282-018-0918-9. Epub 2018 Oct 22.

PMID:
30350259
37.

High-throughput screening in colorectal cancer tissue-originated spheroids.

Kondo J, Ekawa T, Endo H, Yamazaki K, Tanaka N, Kukita Y, Okuyama H, Okami J, Imamura F, Ohue M, Kato K, Nomura T, Kohara A, Mori S, Dan S, Inoue M.

Cancer Sci. 2019 Jan;110(1):345-355. doi: 10.1111/cas.13843. Epub 2018 Nov 20.

38.

Neuroplastic changes in the olfactory bulb associated with nasal inflammation in mice.

Hasegawa-Ishii S, Shimada A, Imamura F.

J Allergy Clin Immunol. 2019 Mar;143(3):978-989.e3. doi: 10.1016/j.jaci.2018.09.028. Epub 2018 Oct 10.

PMID:
30315829
39.

Fatty acid biomarkers of dairy fat consumption and incidence of type 2 diabetes: A pooled analysis of prospective cohort studies.

Imamura F, Fretts A, Marklund M, Ardisson Korat AV, Yang WS, Lankinen M, Qureshi W, Helmer C, Chen TA, Wong K, Bassett JK, Murphy R, Tintle N, Yu CI, Brouwer IA, Chien KL, Frazier-Wood AC, Del Gobbo LC, Djoussé L, Geleijnse JM, Giles GG, de Goede J, Gudnason V, Harris WS, Hodge A, Hu F; InterAct Consortium, Koulman A, Laakso M, Lind L, Lin HJ, McKnight B, Rajaobelina K, Risérus U, Robinson JG, Samieri C, Siscovick DS, Soedamah-Muthu SS, Sotoodehnia N, Sun Q, Tsai MY, Uusitupa M, Wagenknecht LE, Wareham NJ, Wu JH, Micha R, Forouhi NG, Lemaitre RN, Mozaffarian D; Fatty Acids and Outcomes Research Consortium (FORCE).

PLoS Med. 2018 Oct 10;15(10):e1002670. doi: 10.1371/journal.pmed.1002670. eCollection 2018 Oct.

40.

Radiation Dose Escalation in Accelerated Hyperfractionated Radiotherapy for Stage III Non-small-cell Lung Cancer.

Wada K, Kishi N, Kanayama N, Hirata T, Morimoto M, Konishi K, Imamura F, Teshima T, Ogawa K.

Anticancer Res. 2018 Oct;38(10):5951-5958. doi: 10.21873/anticanres.12941.

PMID:
30275224
41.

Genome-wide association study for risk taking propensity indicates shared pathways with body mass index.

Clifton EAD, Perry JRB, Imamura F, Lotta LA, Brage S, Forouhi NG, Griffin SJ, Wareham NJ, Ong KK, Day FR.

Commun Biol. 2018 May 3;1:36. doi: 10.1038/s42003-018-0042-6. eCollection 2018.

42.

Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.

Uchibori K, Satouchi M, Sueoka-Aragane N, Urata Y, Sato A, Imamura F, Inoue T, Tachihara M, Kobayashi K, Katakami N, Kokan C, Hirashima T, Iwanaga K, Mori M, Aoe K, Morita S, Negoro S.

Lung Cancer. 2018 Oct;124:65-70. doi: 10.1016/j.lungcan.2018.07.031. Epub 2018 Jul 23.

PMID:
30268482
43.

Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset.

Cho BC, Chewaskulyong B, Lee KH, Dechaphunkul A, Sriuranpong V, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cheng Y, Cho EK, Voon PJ, Lee JS, Mann H, Saggese M, Reungwetwattana T, Ramalingam SS, Ohe Y.

J Thorac Oncol. 2019 Jan;14(1):99-106. doi: 10.1016/j.jtho.2018.09.004. Epub 2018 Sep 18.

PMID:
30240852
44.

Assessing dietary intakes from household budget surveys: A national analysis in Bangladesh.

Karageorgou D, Imamura F, Zhang J, Shi P, Mozaffarian D, Micha R.

PLoS One. 2018 Aug 27;13(8):e0202831. doi: 10.1371/journal.pone.0202831. eCollection 2018.

45.

Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor.

Kunimasa K, Nakamura H, Sakai K, Kimura M, Inoue T, Tamiya M, Nishino K, Kumagai T, Nakatsuka S, Endo H, Inoue M, Nishio K, Imamura F.

Ann Oncol. 2018 Oct 1;29(10):2145-2147. doi: 10.1093/annonc/mdy312. No abstract available.

PMID:
30099497
46.

Nivolumab induced vitiligo-like lesions in a patient with metastatic squamous cell carcinoma of the lung.

Nishino K, Ohe S, Kitamura M, Kunimasa K, Kimura M, Inoue T, Tamiya M, Kumagai T, Nakatsuka SI, Isei T, Imamura F.

J Thorac Dis. 2018 Jun;10(6):E481-E484. doi: 10.21037/jtd.2018.05.104. No abstract available.

47.

Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer.

Shiroyama T, Suzuki H, Tamiya M, Tamiya A, Tanaka A, Okamoto N, Nakahama K, Taniguchi Y, Isa SI, Inoue T, Imamura F, Atagi S, Hirashima T.

Anticancer Res. 2018 Aug;38(8):4723-4729. doi: 10.21873/anticanres.12779.

PMID:
30061241
48.

Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy.

Shibuya H, Hijioka S, Sakamoto Y, Ito T, Ueda K, Komoto I, Kobayashi N, Kudo A, Yasuda H, Miyake H, Arita J, Kiritani S, Ikeda M, Imaoka H, Ueno M, Kobayashi S, Furuta M, Nagashio Y, Murohisa G, Aoki T, Matsumoto S, Motoya M, Azemoto N, Itakura J, Horiguchi S, Yogi T, Kawagoe T, Miyaoka Y, Imamura F, Senju M, Arioka H, Hara K, Imamura M, Okusaka T.

Cancer Chemother Pharmacol. 2018 Oct;82(4):661-668. doi: 10.1007/s00280-018-3656-y. Epub 2018 Jul 27.

PMID:
30054710
49.

Proliferative CD8(+) PD-1(+) T-cell infiltration in a pembrolizumab-induced cutaneous adverse reaction.

Kunimasa K, Isei T, Nakamura H, Kimura M, Inoue T, Tamiya M, Nishino K, Kumagai T, Nakatsuka SI, Endo H, Inoue M, Imamura F.

Invest New Drugs. 2018 Dec;36(6):1138-1142. doi: 10.1007/s10637-018-0628-3. Epub 2018 Jun 26.

PMID:
29947012
50.

Association Between Imaging Findings of Airway Obstruction Adjacent to Lung Tumors and the Onset of Interstitial Lung Disease After Nivolumab.

Nakahama K, Tamiya A, Isa SI, Taniguchi Y, Shiroyama T, Suzuki H, Inoue T, Tamiya M, Hirashima T, Imamura F, Atagi S.

In Vivo. 2018 Jul-Aug;32(4):887-891. doi: 10.21873/invivo.11324.

Supplemental Content

Loading ...
Support Center